Caprock Group LLC Buys 717 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Caprock Group LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 33.6% during the 2nd quarter, Holdings Channel.com reports. The fund owned 2,853 shares of the company’s stock after acquiring an additional 717 shares during the period. Caprock Group LLC’s holdings in IDEXX Laboratories were worth $1,390,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Riverview Trust Co purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at about $26,000. Crewe Advisors LLC purchased a new stake in IDEXX Laboratories in the 1st quarter valued at about $26,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $28,000. Finally, DSM Capital Partners LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $33,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

IDXX opened at $480.34 on Tuesday. The firm has a 50-day moving average price of $479.87 and a 200-day moving average price of $502.90. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $39.54 billion, a price-to-earnings ratio of 46.50, a PEG ratio of 4.02 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.67 earnings per share. Equities analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on IDXX shares. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. BTIG Research began coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target for the company. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a report on Tuesday, May 14th. Finally, Piper Sandler dropped their target price on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $582.25.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.